#Rapid Diagnostics | Explore Tumblr posts and blogs

creativeera · 6 months ago

Text

Point of Care Diagnostics: Revolutionizing Healthcare with Real-Time Testing

The Advent of Quick and Accurate Medical Testing Point of Care Diagnostics have emerged as a groundbreaking development in the medical field by enabling accurate testing to be done quickly and conveniently. Traditional diagnostic methods usually require samples to be sent to a centralized laboratory for analysis, which can delay vital treatment decisions by several days. However, point-of-care tests provide results within minutes using portable devices, bringing testing closer to the patient. This revolutionary approach is transforming healthcare delivery. Rapid Testing for Better Patient Outcomes By facilitating timely diagnosis, point-of-care testing leads to better patient outcomes. Speedy detection of conditions like infections or chronic diseases allows doctors to prescribe appropriate treatment without delay. For example, point-of-care tests are commonly used in emergency rooms to quickly identify heart attacks, strokes or life-threatening infections. Getting fast diagnostic results is crucial for such medical emergencies as it ensures patients receive the right therapy as soon as possible. The timely administration of antibiotics, anti-clotting medications or other critical treatments improves survival rates and recovery. Patient Comfort and Convenience Besides clinical benefits, Point of Care Diagnostics enhance patient comfort and convenience. People no longer have to wait anxiously for days to learn about their health while potentially worsening conditions go untreated. With devices that analyze samples on-site, patients get actionable results during the same clinical visit when treatment decisions are made. This spares them follow-up trips to the doctor or lab and unnecessary stress. Home testing using self-administered point-of-care kits even allows monitoring health remotely while maintaining independence. Finger-prick blood samples or urine specimens are all that's needed, eliminating difficulties obtaining specimens. More Efficient Use of Resources Speedy diagnostic testing optimizes use of limited healthcare resources. Quick turnaround times avoid unnecessary reliance on expensive treatments initiated just to address uncertainty in diagnoses. Point-of-care devices reduce laboratory workloads too by decentralizing testing. Moreover, decentralized testing is vital for resource-constrained settings like rural areas, refugee camps or developing countries where access to centralized labs is limited. Portable devices overcome infrastructure barriers and enable basic medical services even in remote areas. This promotes healthcare equity globally. A Proliferation of Diagnostic Platforms Rapid technological progress has enabled the development of varied point-of-care testing systems. Examples include paper microfluidic devices, electrochemical sensors, molecular diagnostics platforms and portable ultrasound machines integrated with imaging analysis software. Immunology-based tests detecting proteins or antibodies through lateral flow or microarray methods are commonly used for conditions like infections and cardiac markers. Molecular diagnostic platforms employ techniques like polymerase chain reaction (PCR) for swift nucleic acid amplification and analysis of viruses or genetic markers. Newer technologies like CRISPR gene editing also hold promise as a basis for point-of-care genetic testing. With ongoing research, the types of conditions examinable at the point of care continue expanding in scope and complexity. Get more insights on Point Of Care Diagnostics

Also read related article on Gastroesophageal Reflux Disease Treatment Devices Market

For Deeper Insights, Find the Report in the Language that You want

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

#Point Of Care Diagnostics #Poc Testing #Rapid Diagnostics #Bedside Testing #Portable Diagnostics #PointOfCare Testing #Poc Devices #NearPatient Testing #Decentralized Diagnostics

0 notes

savibangar · 1 year ago

Text

Rapid Diagnostics Market: Builds for Its Future

According to a new market research report titled "Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose, Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals, Diagnostic Labs, Home Care) — Global Forecasts to 2029", published by Meticulous Research®, the rapid diagnostics market is expected to grow at a CAGR of 8.9% from 2022–2029 to reach $18.20 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5240

A rapid diagnostic test (RDT) is a medical diagnostic test intended to provide diagnostic results efficiently and immediately (within 1 hour). RDT kits are widely used in hospitals, clinics, and diagnostic laboratories for the qualitative and quantitative detection of specific antigens, antibodies, and genetic material or proteins associated with a specific health condition or disease.

The growth of the overall RDT market is driven by key factors, such as the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, and emerging technological innovations.

Rapid Diagnostics Market: Outlook

The overall rapid diagnostics market is segmented based on product (kits and test readers/analyzers), platform (immunoassays, molecular detection, and other platforms), application (blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, urinalysis, and cholesterol testing), end user (hospitals & clinics, diagnostic laboratories, home care/self testing, and other end users) and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5240

Based on product type, the kits segment is estimated to account for the largest share of the overall rapid diagnostics market in 2022. The large share of this segment is attributed to the rising adoption and repetitive kits usage. In addition, the growing portfolio of disease-specific kits for the early diagnosis of chronic diseases and the increasing technological advancements are other factors supporting the growth of this segment. However, the test readers/analyzers segment is expected to witness the fastest growth rate during the forecast period. The high growth rate of this segment is attributed to the capabilities of these devices to simultaneously read multiple tests in one scan and scale large volumes. In addition, healthcare facilities adopt analyzers for quick analysis compared to centralized lab analyzers due to their features, such as compact size, portability, and easy accessibility.

Based on platform, the immunoassays segment is estimated to account for the largest share of the overall rapid diagnostics market in 2022. The large share of this segment is attributed to the capability of immunoassay kits to provide fast and accurate results with high sensitivity in point-of-care diagnostics. Countries worldwide require rapid and accurate SARS-CoV-19 testing kits to tackle the COVID-19 pandemic. Thus, companies have started developing immunoassay kits that provide results with higher sensitivity, accuracy, and speed. For instance, in May 2021, Stream Bio (U.K.) and Chelsea Technologies (U.K.) formed a joint venture, Brightline Diagnostics (DX), and created a unique platform known as Claritas that couples fluorescent lateral flow test with a highly sensitive handheld reader, delivering significant advantages over existing assays. However, the molecular detection segment is expected to witness the fastest growth rate during the forecast period. The growing need for advanced diagnostic techniques and the launch of innovative technologies are factors attributed to the high growth rate of this segment. In addition, the high demand for rapid PCR diagnostic kits due to the COVID-19 pandemic further boost the growth of this segment. For instance, countries such as Japan and India rely heavily on RT-PCR kits to diagnose and manage COVID-19 infections. Also, numerous countries worldwide have made negative COVID-19 RT-PCR test reports mandatory for international and local travelers.

Quick Buy – Rapid Diagnostics Market Research Report: https://www.meticulousresearch.com/Checkout/74262428

Based on application, the infectious disease testing segment is estimated to account for the largest share of the rapid diagnostics market in 2022. The large share of this segment is mainly attributed to the rising prevalence of infectious diseases and the growing demand for affordable infectious disease testing in emerging markets. For instance, in the U.S., the number of estimated new hepatitis A virus (HAV) infections increased by nearly three folds in 2017 compared to 2014. However, the tumor/cancer markers testing segment is expected to witness the fastest growth rate during the forecast period. The growing incidences of cancer among the general population is the major factor attributed to the high growth rate of this segment. According to WHO, cancer was the leading cause of death globally in 2020, accounting for approximately 10 million deaths. Furthermore, nearly 70% of deaths out of the total deaths from cancer occur in low- and middle-income countries; therefore, early detection is extremely important to reduce mortality, enhance survival, and save treatment costs. Thus, healthcare workers utilize various rapid diagnostic kits for the early detection of cancer.

Based on end user, the hospitals & clinics segment is expected to witness the fastest growth rate in the forecast period. The rising number of hospitals worldwide and the increase in healthcare access & expenditure are attributed to the high growth rate of this segment. For instance, the American Hospital Association has reported that the total number of registered hospitals in the U.S. was estimated to grow by 12% to 6,210 in 2019 from 5,534 hospitals in 2018. Similarly, in India, according to the Health Management Information System Portal (HMIS), as of 2018, there were around 37,725 hospitals, which was an increase of 7.0% from 35,416 hospitals in 2013.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5240

Geographically, North America is estimated to command the largest share of the global rapid diagnostics market in 2022, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. The large market share of this region is mainly attributed to the high number of laboratory tests performed annually in North America, the rising prevalence of chronic diseases coupled with the increasing aging population, and the rising number of inpatient hospitalizations. For instance, the U.S. Department of Health and Human Services reported that the number of patients with HIV is growing with a CAGR of 2.5% in the country. It is assumed that 40% of new HIV infections in the U.S. are transmitted by people living with undiagnosed HIV; this boosts the demand for related rapid testing products throughout the country.

However, Asia-Pacific region is expected to be the fastest-growing regional market due to the growing geriatric population, the rising prevalence of infectious & chronic diseases, and various government initiatives to promote health awareness.

Key companies operating in the global rapid diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland) among others.

TOP 10 COMPANIES IN RAPID DIAGNOSTICS MARKET @ https://meticulousblog.org/top-10-companies-in-rapid-diagnostics-market/?utm_source=pr&utm_medium=social+&utm_campaign=product&utm_content=07-12-2023

#Rapid Diagnostics Market #Rapid Diagnostics #Lateral Flow #Serological #PCR

0 notes